Evidence map›Paper›PMID 32604979›Full record

ArticleInternational journal of molecular sciences2020

Naringenin-Functionalized Multi-Walled Carbon Nanotubes: A Potential Approach for Site-Specific Remote-Controlled Anticancer Delivery for the Treatment of Lung Cancer Cells.

Renata P Morais, Gabrielle B Novais, Leandro S Sangenito, André L S Santos, Ronny Priefer, Margreet Morsink, Marcelo C Mendonça, Eliana B Souto, Patrícia Severino, Juliana C Cardoso

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Review
  3. An Updated Review Summarizing the Anticancer Potential of Naringenin.Endocrine, metabolic & immune disorders drug targets · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Renata P MoraisTiradentes University (UNIT), 300, Murilo Dantas Ave, Farolândia 49032-490, Brazil.ORCID 0000-0002-6341-9365
Gabrielle B NovaisTiradentes University (UNIT), 300, Murilo Dantas Ave, Farolândia 49032-490, Brazil.
Leandro S SangenitoFederal University of Rio de Janeiro (UFRJ), 373, Carlos Chagas Filho Ave, Cidade Universitária da Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-901, Brazil.
André L S SantosFederal University of Rio de Janeiro (UFRJ), 373, Carlos Chagas Filho Ave, Cidade Universitária da Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-901, Brazil.ORCID 0000-0003-0821-8592
Ronny PrieferSchool of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, MA 02115, USA.ORCID 0000-0002-4586-0405
Margreet MorsinkCenter for Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA.ORCID 0000-0001-5511-6105
Marcelo C MendonçaTiradentes University (UNIT), 300, Murilo Dantas Ave, Farolândia 49032-490, Brazil.ORCID 0000-0001-6003-4796
Eliana B SoutoDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.ORCID 0000-0002-9737-6017
Patrícia SeverinoTiradentes University (UNIT), 300, Murilo Dantas Ave, Farolândia 49032-490, Brazil.ORCID 0000-0001-6527-6612
Juliana C CardosoTiradentes University (UNIT), 300, Murilo Dantas Ave, Farolândia 49032-490, Brazil.
Universidade Tiradentes · BRUniversidade Federal do Rio de Janeiro · BRBrigham and Women's Hospital · USMassachusetts College of Pharmacy and Health Sciences · USUniversity of Coimbra · PT

Funding

Banco do Nordeste grant FUNDECI/2016.0015Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Apoio à Pesquisa e à Inovação Tecnológica do Estado de Sergipe (Fapitec) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) CNPq, FAPITEC, CAPESPortuguese Science and Technology Foundation M-ERA-NET/0004/2015-PAIRED and UIDB/04469/2020 (strategic fund)
6 · The paper itself

Abstract

Multi-walled carbon nanotubes functionalized with naringenin have been developed as new drug carriers to improve the performance of lung cancer treatment. The nanocarrier was characterized by Transmission Electron Microscopy (TEM), Fourier-Transform Infrared Spectroscopy (FTIR), X-ray photoelectron spectroscopy, Raman Spectroscopy, and Differential Scanning Calorimetry (DSC). Drug release rates were determined in vitro by the dialysis method. The cytotoxic profile was evaluated using the MTT assay, against a human skin

Indexed as

Drug LiberationAntineoplastic AgentsApoptosisCell ProliferationDrug CarriersFlavanonesHumansLung NeoplasmsNanotubes, CarbonTumor Cells, CulturedAntineoplastic AgentsDrug CarriersFlavanonesNanotubes, Carbonnaringeninantineoplastic agentscarbon nanotubesflavanonesfunctionalizationlung cancernaringenin

Identifiers

PMID32604979
PMCPMC7348916
OpenAlexW3037441524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.